Art. 8 Directive (EU) 2001/83

In forcesince 1 Jan 2022cited 101×
1.

In order to obtain an authorization to place a medicinal product on the market regardless of the procedure established by Regulation (EEC) No 2309/93, an application shall be made to the competent authority of the Member State concerned.

2.

A marketing authorization may only be granted to an applicant established in the Community.

2a.

By way of derogation from paragraph 2, marketing authorisations may be granted by the competent authorities of the United Kingdom in respect of Northern Ireland to applicants established in parts of the United Kingdom other than Northern Ireland.

2b.

By way of derogation from paragraph 2, marketing authorisations may be granted by the competent authorities of the United Kingdom in respect of Northern Ireland and, until 31 December 2024, by the competent authorities of Cyprus, Ireland and Malta, in accordance with the mutual recognition or the decentralised procedure laid down in Chapter 4 of this Title, to marketing authorisation holders established in parts of the United Kingdom other than Northern Ireland.

The competent authorities of the United Kingdom in respect of Northern Ireland and, until 31 December 2024, the competent authorities of Cyprus, Ireland and Malta may extend marketing authorisations already granted prior to 20 April 2022 to marketing authorisation holders established in parts of the United Kingdom other than Northern Ireland.

The marketing authorisations granted or extended by the competent authorities of Cyprus, Ireland or Malta in accordance with the first and second subparagraph shall cease to be valid at the latest on 31 December 2026.

3.

The application shall be accompanied by the following particulars and documents, submitted in accordance with Annex I:

(a)

Name or corporate name and permanent address of the applicant and, where applicable, of the manufacturer.

(b)

Name of the medicinal product.

(c)

Qualitative and quantitative particulars of all the constituents of the medicinal product, including the reference to its international non-proprietary name (INN) recommended by the WHO, where an INN for the medicinal product exists, or a reference to the relevant chemical name.

(ca)

Evaluation of the potential environmental risks posed by the medicinal product. This impact shall be assessed and, on a case-by-case basis, specific arrangements to limit it shall be envisaged.

(d)

Description of the manufacturing method.

(e)

Therapeutic indications, contra-indications and adverse reactions.

(f)

Posology, pharmaceutical form, method and route of administration and expected shelf life.

(g)

Reasons for any precautionary and safety measures to be taken for the storage of the medicinal product, its administration to patients and for the disposal of waste products, together with an indication of potential risks presented by the medicinal product for the environment.

(h)

Description of the control methods employed by the manufacturer.

(ha)

A written confirmation that the manufacturer of the medicinal product has verified compliance of the manufacturer of the active substance with principles and guidelines of good manufacturing practice by conducting audits, in accordance with point (f) of Article 46. The written confirmation shall contain a reference to the date of the audit and a declaration that the outcome of the audit confirms that the manufacturing complies with the principles and guidelines of good manufacturing practice.

(i)

Results of:

pharmaceutical (physico-chemical, biological or microbiological) tests,

pre-clinical (toxicological and pharmacological) tests,

clinical trials.

(ia)

A summary of the applicant’s pharmacovigilance system which shall include the following elements:

proof that the applicant has at his disposal a qualified person responsible for pharmacovigilance,

the Member States in which the qualified person resides and carries out his/her tasks,

the contact details of the qualified person,

a statement signed by the applicant to the effect that the applicant has the necessary means to fulfil the tasks and responsibilities listed in Title IX,

a reference to the location where the pharmacovigilance system master file for the medicinal product is kept.

(iaa) The risk management plan describing the risk management system which the applicant will introduce for the medicinal product concerned, together with a summary thereof.

(ib)

A statement to the effect that clinical trials carried out outside the European Union meet the ethical requirements of Directive 2001/20/EC.

(j)

A summary, in accordance with Article 11, of the product characteristics, a mock-up of the outer packaging, containing the details provided for in Article 54, and of the immediate packaging of the medicinal product, containing the details provided for in Article 55, together with a package leaflet in accordance with Article 59.

(k)

A document showing that the manufacturer is authorised in his own country to produce medicinal products.

(l)

Copies of the following:

any authorisation, obtained in another Member State or in a third country, to place the medicinal product on the market, a summary of the safety data including the data contained in the periodic safety update reports, where available, and suspected adverse reactions reports, together with a list of those Member States in which an application for authorisation submitted in accordance with this Directive is under examination;

the summary of the product characteristics proposed by the applicant in accordance with Article 11 or approved by the competent authorities of the Member State in accordance with Article 21 and the package leaflet proposed in accordance with Article 59 or approved by the competent authorities of the Member State in accordance with Article 61;

details of any decision to refuse authorisation, whether in the Union or in a third country, and the reasons for such a decision.

(m)

A copy of any designation of the medicinal product as an orphan medicinal product under Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products [OJ L 18, 22.1.2000, p. 1.], accompanied by a copy of the relevant Agency opinion.

(n)

Proof that the applicant has the services of a qualified person responsible for pharmacovigilance and has the necessary means for the notification of any adverse reaction suspected of occurring either in the Community or in a third country.

The documents and information concerning the results of the pharmaceutical and pre-clinical tests and the clinical trials referred to in point (i) of the first subparagraph shall be accompanied by detailed summaries in accordance with Article 12.

The risk management system referred to in point (iaa) of the first subparagraph shall be proportionate to the identified risks and the potential risks of the medicinal product, and the need for post-authorisation safety data.

The information referred to in the first subparagraph shall be updated where and when appropriate.

The 10 that are cited most themselves, of 101.

  • Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…16Law

    … по отношение на методите на производство и контрол, посочени в член 8, параграф 3, букви г) и з) от Директива 2001/83/ЕО, и въвежда всички …

  • Directive (EU) 2004/27Lawamends

  • Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 Decembe…7Law

    … в допълнение към подробностите и документите, посочени в член 8, параграф 3 от Директива 2001/83/ЕО, един от следните документи: а) …

  • Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination o…2Law

    … за проследяване на лекарствената безопасност, посочена в член 8, параграф 3, буква иa) от Директива 2001/83/ЕО. 9. Всички промени в …

  • Judgment of the General Court (Seventh Chamber, Extended Composition) of 5 May 2021. Pharmaceutical Works Polpharma S.A. v European MedicineDecision

    Lastly, it should be noted that, in the implementing decision of 30 January 2014, the Commission found that Tecfidera containing DMF differed from Fumaderm, the other already authorised medicinal product containing DMF and MEF salts, and …

    5 May 2021 · 62018TJ0611

  • Judgment of the Court (Fourth Chamber) of 16 March 2023. European Commission and Others v Pharmaceutical Works Polpharma S.A.Decision

    … »[Tecfidera]«, hvis anvendelse var baseret på artikel 8, stk. 3, i direktiv [2001/83], og det allerede godkendte lægemiddel Fumaderm hører derfor ikke ind under samme samlede markedsføringstilladelse, jf. [dette direktivs] artikel 6, …

    16 Mar 2023 · 62021CJ0438

  • Judgment of the Court (Eighth Chamber) of 28 June 2017. Novartis Europharm Ltd v European Commission.Decision

    Article 8(3) of Directive 2001/83 provides as follows: ‘The application [for a marketing authorisation] shall be accompanied by the following particulars and documents … : ... Results of: Pharmaceutical (physico-chemical, biological or …

    28 Jun 2017 · 62015CJ0629

  • Judgment of the Court (Fifth Chamber), 23 October 2014. Olainfarm AS v Latvijas Republikas Veselības ministrija and Zāļu valsts aģentūra.Decision

    The term ‘reference medicinal product’ is defined in Article 10(2)(a) of Directive 2001/83 as a medicinal product authorised under Article 6 of the directive, in accordance with the provisions of Article 8 thereof.

    23 Oct 2014 · 62013CJ0104

  • Judgment of the Court (Second Chamber) of 14 March 2018. Proceedings brought by Astellas Pharma GmbH.Decision

    Article 8(3)(i) of Directive 2001/83 provides that the application for marketing authorisation is to be accompanied by the results of pharmaceutical (physico-chemical, biological or microbiological) tests, pre-clinical (toxicological and …

    14 Mar 2018 · 62016CJ0557

  • Judgment of the Court (First Chamber) of 18 June 2009. The Queen, on the application of Generics (UK) Ltd v Licensing Authority.Decision

    In order to reply to that question, it should be recalled, at the outset, that the objective of the obligation on applicants seeking marketing authorisation for a medicinal product, to attach to the application the results of toxicological …

    18 Jun 2009 · 62007CJ0527